Volume 64, Issue 6, Pages (June 2016)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Primary prevention of variceal haemorrhage: A pharmacological approach
Volume 61, Issue 6, Pages (December 2014)
Volume 51, Issue 6, Pages (December 2009)
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Volume 42, Issue 4, Pages (April 2005)
Volume 66, Issue 1, Pages 1-4 (January 2017)
The evidence supports a viral aetiology for primary biliary cirrhosis
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Living donor liver transplantation: is the hype over?
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
Mesenchymal stromal cell therapy for liver diseases
The place of downstaging for hepatocellular carcinoma
Reply to: “Low free T3 levels are related to early mortality in patients with decompensated cirrhosis and acute-on chronic liver failure”  Rakhi Maiwall,
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Volume 43, Issue 4, Pages (October 2005)
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Economics of chronic hepatitis B and hepatitis C
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Volume 42, Issue 6, Pages (June 2005)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 56, Issue 6, Pages (June 2012)
Immigration and viral hepatitis
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Immunological techniques in viral hepatitis
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
The use of hemospray in portal hypertensive bleeding; a case series
Volume 66, Issue 4, Pages (April 2017)
HCV animal models and liver disease
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Chimeric mouse model of hepatitis B virus infection
A 360-degree overview of paediatric NAFLD: Recent insights
The relationship between age and fat infiltration in liver and muscle
Genetics of hepatocellular carcinoma: The next generation
MELD: the holy grail of organ allocation?
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Presentation transcript:

Volume 64, Issue 6, Pages 1203-1205 (June 2016) Not all mice are the same: Standardization of animal research data presentation    Journal of Hepatology  Volume 64, Issue 6, Pages 1203-1205 (June 2016) DOI: 10.1016/j.jhep.2016.04.007 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Key elements to consider and highlight for mouse related studies. The schematic shows several important criteria that need to be considered when planning mouse (and other animal) experiments, and when submitting work for publication. FVB and C57BL/6 represent, as examples, commonly used mouse strains. Of note, vendor sources can also be important (eg, FVB/NJ from The Jackson Laboratory vs. FVB/NTac from Taconic). Other considerations not displayed in the schematic, such as environment conditions, are highlighted in the text. +/+, wild-type littermate mice; −/−, knockout littermate mice. Journal of Hepatology 2016 64, 1203-1205DOI: (10.1016/j.jhep.2016.04.007) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions